Alligator Bioscience AB (publ) (STO:ATORX)
Sweden flag Sweden · Delayed Price · Currency is SEK
5.77
+0.02 (0.26%)
Aug 1, 2025, 5:29 PM CET

Alligator Bioscience AB Company Description

Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Finland and Sweden.

The company develops Mitazalimab, a stimulatory antibody that targets CD40, which is in phase 2 clinical trial for the treatment of solid metastatic tumors, including pancreatic cancer; and ATOR-4066, tumor-directed bispecific antibody, developed using Neo-X-Prime technology platform for immunotherapy, which is in preclinical stage for the treatment of solid metastatic tumors.

It also offers ALG.APV-527, a bispecific antibody that targets the 4-1BB and 5T4 molecules, which is in phase 1 clinical trial for the treatment of solid metastatic tumors; and ATOR-1017, a monoclonal antibody that stimulates the 4-1BB receptor on T cells and NK cells in the tumor, which is in phase 1 for the treatment of solid metastatic cancers.

In addition, the company develops products using its technology platforms, including ALLIGATOR-GOLD, a proprietary human antibody library; ALLIGATOR-FAB, which is built on multiple scaffolds with optimal drug development properties to further increase the structural diversity of generated antibodies; FIND, a molecular evolution technology for optimization of antibodies and other proteins; and RUBY, a bispecific antibody format.

Further, it has collaboration and out-licensing agreements with Aptevo Therapeutics, Inc.; Orion Corporation.; BioArctic AB; and Abclon Inc. The company was incorporated in 2000 and is headquartered in Lund, Sweden.

Alligator Bioscience AB (publ)
Alligator Bioscience AB logo
CountrySweden
Founded2000
IndustryBiotechnology
SectorHealthcare
Employees45
CEOSøren Bregenholt

Contact Details

Address:
Medicon Village
Lund, 223 81
Sweden
Phone46 4 65 40 82 00
Websitealligatorbioscience.se

Stock Details

Ticker SymbolATORX
ExchangeNasdaq Stockholm
Fiscal YearJanuary - December
Reporting CurrencySEK
ISIN NumberSE0000767188
SIC Code2836

Key Executives

NamePosition
Søren Bregenholt Ph.D.Chief Executive Officer
Johan GileusChief Financial Officer
Greta EklundInvestor Relations and Communications Manager
Dr. Tom MooreChief Medical Officer